Jazz Pharmaceuticals revenue and financials

JAZZ · NASDAQ · USD

$231.39−1.97%−$4.65

Close · October 6, 2026

In the fiscal year ended December 2025, Jazz Pharmaceuticals reported revenue of $4.27B (+4.88% year over year). The net loss was $356.15M.

Annual revenue · 2025: $4.27B

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total revenue	1,208	1,069	1,198	1,126	1,046	898	1,088	1,055	1,024	902	1,012	972
Cost of revenue	116	96.6	113	129	116	74.7	90.9	112	110	66.5	74.9	102
Gross profit	1,092	972	1,085	997	929	823	997	943	914	835	937	870
Selling, general and administrative	389	353	418	379	358	514	400	326	339	352	360	308
Research and development	208	196	173	198	190	181	208	200	221	223	191	234
Operating income	325	251	324	252	219	-26.0	231	260	199	105	235	172
EBIT	325	251	324	252	219	-26.0	231	260	199	105	235	172
EBITDA	504	433	503	430	393	139	399	425	362	269	394	335
Interest expense	62.4	63.3	65.9	67.2	66.5	81.3	83.0	84.7	87.4	89.4	91.0	90.7
Pre-tax income	211	299	208	9.0	-736	-110	133	201	138	-2.9	61.1	99.6
Income tax	18.1	6.1	5.0	-242	-17.2	-17.8	-57.9	-14.5	-30.7	11.7	-33.1	-47.2
Net income	193	293	203	251	-719	-92.5	191	215	169	-14.6	94.2	147
Net income to common shareholders	193	293	203	251	-719	-92.5	191	215	169	-14.6	94.2	147
Basic EPS	3.05	4.74	3.33	4.14	-11.74	-1.52	3.16	3.50	2.68	-0.23	1.50	2.33
Diluted EPS	2.78	4.43	3.21	4.08	-11.74	-1.52	3.11	3.42	2.49	-0.23	1.42	2.14
Average shares (basic)	63.2	61.9	61.1	60.7	61.2	61.0	60.5	61.4	62.9	62.5	62.6	63.1
Average shares (diluted)	69.4	66.1	63.4	61.6	61.2	61.0	61.5	63.2	69.6	62.5	69.7	71.3